EN | UA
EN | UA

Help Support

Back

Multitope COVID-19 vaccine offers long-lasting immunity against COVID-19 variants

Multitope_COVID-19_vaccine Multitope_COVID-19_vaccine
Multitope_COVID-19_vaccine Multitope_COVID-19_vaccine

What's new?

In healthy adults, UB-612 vaccine promotes long-lasting immunity, and is a safe and potent booster against delta and omicron variants.

A phase I trial revealed that UB-612 (a multitope subunit COVID-19 vaccine) exhibits a promising safety profile, effective booster effect against COVID-19 variants of concern (VoCs), and long-lasting B and broad T cell immunity. Chang Yi Wang et al. aimed to report the phase I/II trial findings of a multitope SARS-CoV-2 vaccine in healthy adults.

Overall, 60 young healthy adults (20-55 years of age) were recruited in the phase I primary 2-dose (28 days apart) trial. The recruited volunteers were administered 10, 30, or 100 μg UB-612 vaccine. Out of 60, 50 participants were given 100 μg of UB-612 intramuscularly around 7-9 months following the second dose.

Using two doses of 100 μg of UB-612, a distinct placebo-controlled and randomized phase II study was held in 18-85 years old healthy adults (n = 3,875). Assessment of immunogenicity and interim safety of phase I until fourteen days following the third dose (booster) and of phase II until twenty-eight days following the second dose was carried out.

No vaccine-associated serious side effects were witnessed. Pain at the injection site and fatigue were the frequently observed adverse events, generally short-lived and mild. The vaccine induced neutralizing antibody titers that were comparable to the panel of human convalescent sera in both trials.

The broad T cell immunity against COVID-19 VoCs, long-lasting virus-neutralizing antibodies, and robust booster-recalled memory immunity with elevated cross-reactive neutralizing titers against coronavirus VoCs (Delta and Omicron) were also reported with the use of UB-612 vaccine. Additional advancement of the UB-612 vaccine is warranted for primary immunization effect and heterologous boosting of the other SARS-CoV-2 vaccines.

Source:

Journal of Clinical Investigation

Article:

A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants

Authors:

Chang Yi Wang et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: